HIV Scientific Papers

Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
2020
Le Hingrat Q, Collin G, Charpentier C, et al.
Poster #PEB0122 presented at: 23rd Annual International AIDS Conference; July 6-10 2020; virtual.
Comparable efficacy of ibalizumab in combination with 1 or 2 fully active agents [abstract].
2020
Top Antivir Med.
DeJesus E, McGary C, Mesquita P, et al.
28 (1):181. Proceedings of the 2020 Conference on Retroviruses and Opportunistic Infections.
Comparable efficacy of ibalizumab in combination with 1 or 2 fully active agents.
2020
DeJesus E, McGary C, Mesquita P, et al.
Poster #507 presented at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts, USA.
Treatment with growth hormone releasing hormone analog reduces VEGF-A, TGFfβ-1, and CSF-1: Mechanisms of tesamorelin effect in nonalcoholic fatty liver disease [abstract].
2020
Hepatology.
Stanley TL, Fourman LT, Billingsley JM, et al.
72(suppl 1):142. Proceedings of The Liver Meeting (AASLD) 2020.
Treatment with growth hormone releasing hormone analog reduces VEGF-A, TGFfβ-1, and CSF-1: Mechanisms of tesamorelin effect in nonalcoholic fatty liver disease.
2020
Fourman LT.
Oral presentation #142 at: Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting); November 13-16, 2020; virtual.